Table 68Serious TEAEs Regardless of Causality — Safety Analysis Set, at Least 2% Patients, Data Cut-Off November 1, 2021

AE preferred term dMMR

(N = 150)

dMMR/MSI-H

(N = 153)

Patients with at least 1 serious TEAE 57 (38.0)58 (37.9)
   Urinary tract infection6 (4.0)6 (3.9)
   Sepsis5 (3.3)5 (3.3)
   Abdominal pain4 (2.7)4 (2.6)
   Acute kidney injury4 (2.7)4 (2.6)
   COVID-193 (2.0)3 (2.0)
   Pneumonia3 (2.0)3 (2.0)
   Pneumonitis3 (2.0)3 (2.0)
   Pulmonary embolism3 (2.0)3 (2.0)
   Pyrexia3 (2.0)3 (2.0)

From: Clinical Review

Cover of Dostarlimab (Jemperli)
Dostarlimab (Jemperli): CADTH Reimbursement Review: Therapeutic area: Endometrial cancer [Internet].
Copyright © 2022 Canadian Agency for Drugs and Technologies in Health.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.